Eriko Tokunaga
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz M, Shimizu C, Huang C, Lueck H, Beith J, Tokunaga E, Contreras J, de Sant'Ana R, Wei R, Shahir A, Nabinger S, Forrester T, Johnston S, Harbeck N. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Ther Adv Med Oncol 2023; 15:17588359231151840.
03.02.2023Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
03.02.2023Ther Adv Med Oncol 2023; 15:17588359231151840
Paluch-Shimon Shani, Neven Patrick, Huober Jens, Cicin Irfan, Goetz Matthew P, Shimizu Chikako, Huang Chiun-Sheng, Lueck Hans Joachim, Beith Jane, Tokunaga Eriko, Contreras Jessica Reyes, de Sant'Ana Rosane Oliveira, Wei Ran, Shahir Ashwin, Nabinger Sarah C, Forrester Tammy, Johnston Stephen R D, Harbeck Nadia
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer
Goetz M, Price G, Gainford M, Andre V, Shekarriz S, Stoffregen C, Toi M, Huober J, Park I, Tokunaga E, Martín M, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020; 25:e1346-e1354.
24.06.2020Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer
24.06.2020Oncologist 2020; 25:e1346-e1354
Goetz Matthew P, Price Gregory L, Gainford M Corona, Andre Valerie, Shekarriz Sarah, Stoffregen Clemens, Toi Masakazu, Huober Jens, Park In Hae, Tokunaga Eriko, Martín Miguel, Johnston Stephen